IGHE and asthma: Interestingly, treatment with monoclonal IgE antibody (omalizumab, Xolair) alleviates allergic reactions and airway damages in asthma by blockade of IgE binding with Fc εRI receptor on the mast cells and other effector cells (Corren et al., 2017).